Avedro Announces Enrollment of First Patient in U.S. Pivotal Phase 3 Epi-on Corneal Cross-Linking Trial for Progressive Keratoconus
Avedro, Inc., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that it has begun enrolling patients in a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of an epithelium-on (epi-on) corneal collagen cross-linking procedure to treat patients with progressive keratoconus. Keratoconus is a non-inflammatory eye condition in which the typically round dome-shaped cornea progressively thins and weakens and is the leading cause of penetrating keratoplasty (corneal transplant) in the United States1.
The Phase 3 clinical trial, ACP-KXL-308, is a multicenter, randomized, controlled study of a novel corneal cross-linking procedure of 275 patients with progressive keratoconus across approximately 20 sites in the United States. As is typical for U.S. Food and Drug Administration (FDA) drug trials, investigational treatments are provided at no cost to participating patients.
“As a practitioner who has treated many patients with progressive keratoconus in previous clinical studies, the commencement of this epi-on cross-linking study represents another important milestone. This procedure, designed to eliminate the need to remove the epithelium, has the potential to be of great value to patients and practices alike,” said Michael B. Raizman, MD, clinical investigator and practicing ophthalmologist at Ophthalmic Consultants of Boston.
“Since the 2016 FDA approval of Avedro’s epi-off cross-linking treatment, thousands of patients with progressive keratoconus, a potentially debilitating disease, have benefited from this procedure,” said Rajesh K. Rajpal, MD, Chief Medical Officer for Avedro and Founder of See Clearly Vision in the Washington D.C. area. “We are proud to continue our efforts to serve these patients and the doctors who treat them with this trial, which is the first and only epi-on study currently intended to support an FDA approval filing.”
“The start of this study is exciting news for patients,” said Mary Prudden, Program Director, National Keratoconus Foundation. “We are pleased to see continued innovation in corneal cross-linking technologies and are hopeful that this research will ultimately lead to a second FDA-approved option for patients living with this rare and sight-threatening condition.”
The current list of participating study sites include Massachusetts, Ohio, Utah, Pennsylvania and Virginia. As new sites are initiated, they will be listed on clinicaltrials.gov.
Avedro is a privately held pharmaceutical and medical device company and the world leader in corneal remodeling. Our patented cross-linking technology, consisting of drug formulations and medical devices, are approved for sale in numerous countries around the globe. We continue to develop proprietary corneal remodeling products for the treatment of keratoconus, corneal ectasia and for refractive correction as an alternative to contacts and eyeglasses. Keratoconus and corneal ectasia are rare and sight-threatening eye conditions in which the cornea progressively thins and weakens causing the development of a cone-like bulge and optical irregularity of the cornea which can result in significant visual impairment.
At Avedro, our mission is to produce and deliver innovative, minimally invasive drugs and devices for corneal remodeling to eyecare professionals around the world to improve patients’ vision and quality of life. For more information, visit www.Avedro.com.
- Borderie VM, Boelle PY, Touzeau O, et al. Predicted long-term Outcome of corneal transplantation. Ophthalmology 2009;2354-2360 Eye Bank Association of America Statistical Report, 2016
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
CHMP Grants Positive Opinion for New Indication of Clovis Oncology’s Rubraca®▼ (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer13.12.2018 17:46 | Pressemelding
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending an additional indication to include rucaparib as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. EC approval is anticipated in the first quarter of 2019. Once approved, Rubraca’s indication will expand beyond its initial Marketing Authorization in Europe granted in May 2018 for adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum-based chemotherapy, and who are unable to tolerate further platinum
Dole Food Company Sells Fresh Cut Business in Sweden and Finland13.12.2018 17:00 | Pressemelding
Dole Food Company, Inc., announced today an agreement to sell Saba Fresh Cuts AB and Saba Fresh Cuts OY to BAMA International. Saba Fresh Cuts AB—with production facility in Helsingborg Sweden—and Saba Fresh Cuts OY—with production facility in Espoo Finland—are producers of washed and ready-to-eat salads. The companies prepare and sell various fresh-cut salads and vegetables to the retail and foodservice industry in Sweden, Denmark, Finland, Germany and the Baltic States. The sale of Saba Fresh Cuts AB was a necessary condition of the European Commission’s approval of the investment by Total Produce into Dole in July 2018. “I am very pleased with the outcome of this sale in meeting the EU’s requirement,” said Mr. Johan Linden, President and Chief Executive Officer of Dole Food Company, “and I am confident that Saba Fresh Cuts will be in good hands under BAMA’s ownership.” "We are pleased to announce this agreement with Dole for Saba Fresh Cuts. Convenience products and ready-to-eat sal
Thales and Gemalto Are Granted Regulatory Clearance by the Commerce Commission in New Zealand13.12.2018 16:00 | Pressemelding
Regulatory News: Reference is made to the joint press release by Thales (Euronext Paris: HO) and Gemalto (Euronext Amsterdam and Paris: GTO) dated 27 March 2018 in relation to the launch of the recommended all-cash offer by Thales for all the issued and outstanding shares of Gemalto (the “Offer”), the publication of the Offer Document, and the joint press release of Thales and Gemalto dated 10 August 2018 in relation to the further extension of the Acceptance Period. Terms not defined in this press release will have the meaning as set forth in the Offer Document. Thales and Gemalto announce today that they have received merger control Regulatory Clearance from the Commerce Commission in New Zealand, following Thales’s commitment to divest its general purpose hardware security modules (GP HSM) business globally1 to a suitable purchaser. This clearance is effective immediately. Together with the antitrust clearances obtained in China, Israel, South Africa, Turkey, and for the European Un
Hurricane Electric Becomes First Internet Backbone to Connect to 200 Internet Exchanges around the Globe13.12.2018 15:37 | Pressemelding
Hurricane Electric, the world’s largest IPv6-native Internet backbone, today announced that it is the first Internet backbone in the world to connect to over 200 unique Internet exchanges. As an early leader in the switch to IPv6, Hurricane Electric now connects to the largest number of networks on the planet for both IPv6 and IPv4 and has been at the forefront of providing high-speed Internet connectivity to organizations throughout the world using:100GE (100 Gigabit Ethernet), 10GE (10 Gigabit Ethernet), and GigE (1 Gigabit Ethernet) connections. As a result of the improved connectivity with these 200 exchanges, customers receive the benefit of lower latency, higher throughput and increased fault tolerance. This reliable connectivity is especially important as global IP traffic continues to increase – Cisco’s Visual Networking Index: Forecast and Trends, 2017–2022 predicts that annual global IP traffic will reach 4.8 zettabytes (ZB) per year by 2022, or 396 exabytes (EB) per month, t
The World's Largest Heritage and Culture Festival to Begin With the Slogan Janadria 33 Faithfulness and Loyalty13.12.2018 15:15 | Pressemelding
With the support and under the patronage of the Custodian of the Two Holy Mosques King Salman bin Abdulaziz, the 33rd Edition of the National Festival of Heritage and Culture will be held in Janadria for 21 days from Thursday 20th December 2018 to Wednesday 9th January 2019. Organized by the Saudi Ministry of National Guard, the festival is part of the efforts to intensify attention to Saudi heritage, expose it regionally and globally and to promote dialogue among cultures and civilizations on the level of people and nations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213005472/en/ The Custodian of the Two Holy Mosques King Salman bin Abdulaziz (Photo: AETOSWire) Janadria is the largest Saudi cultural festival that simulates the history, present and future of Saudi Arabia and the largest event of its kind in the region. Since 1985, it has witnessed extensive Saudi participation, a growing Arab and Gulf presence and an
PPG to Invest in Automated Dispense Cell Manufacturing for Automotive Parts and Accessories13.12.2018 14:32 | Pressemelding
PPG (NYSE: PPG) today announced that it is increasing its investment in automated dispense cell manufacturing of paint and related coatings for the automotive parts and accessories decorative (APAD) space. Financial details are not being disclosed. Dispense cell technology enables PPG to dramatically accelerate production and approval of paint batches for vehicle original equipment manufacturers (OEMs) and component suppliers. The technology allows coatings components to be automatically drawn from storage vats in the correct proportions and mixed directly in their shipping containers, vastly simplifying and increasing the efficiency of the coatings manufacturing process. PPG recently launched an APAD dispense cell operation at its San Juan del Rio, Mexico, coatings facility and will begin production on an additional cell in 2019 in Sriperumbudur, India. These cells are in addition to PPG’s recent APAD investments in Germany and Russia and the dispense cells already online at the Compa